For many years, heart failure pharmacotherapy primarily focused on neurohormonal modulation of the RAAS with angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARBs) and mineralocorticoid receptor blockers (MRAs), as well as the sympathetic nervous system with β blockers. The gene discussed is ACE; the disease is heart failure.